The Alaska Permanent Fund is a constitutionally established permanent fund managed by a state-owned corporation, the Alaska Permanent Fund
Business Model:
Revenue: $9.4B
Employees: 51-200
Address: 801 W 10th Street Suite 302
City: Juneau
State: AK
Zip: 99801
Country: US
The Alaska Permanent Fund is a constitutionally established permanent fund managed by a state-owned corporation, the Alaska Permanent Fund Corporation. The fund was established in Alaska in 1976 by Article 9, Section 15 of the Alaska State Constitution under Governor Jay Hammond. From February 1976 until April 1980, the Department of Revenue Treasury Division managed the state&s;s Permanent Fund assets, until, in 1980, the Alaska State Legislature created the APFC. Shortly after the oil from Alaska’s North Slope began flowing to market through the Trans-Alaska Pipeline System, the Permanent Fund was created. It was designed to be an investment where at least 25% of the oil money would be put into a dedicated fund for future generations, who would no longer have oil as a resource. This does not mean the fund is solely funded by oil revenue. The Alaska Permanent Fund sets aside a certain share of oil revenues to continue benefiting current and all future generations of Alaskans.
Contact Phone:
+19077961500
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
12/2021 | NorthLink Aviation | Venture Round | - |
5/2015 | Denali Therapeutics | Series A | 217M |
8/2020 | Indigo | Series F | 360M |
12/2013 | Juno Therapeutics | Series A | 120M |
4/2021 | Repertoire Immune Medicines | Series B | 0 |
11/2017 | Codiak Biosciences | Series C | 76.5M |
11/2021 | Generate Biomedicines | Series B | 0 |
4/2022 | Tessera Therapeutics | Series C | 0 |
1/2021 | Tessera Therapeutics | Series B | 0 |
8/2014 | Juno Therapeutics | Series B | 134M |
1/2016 | Codiak Biosciences | Series B | 61M |
6/2020 | Sana Biotechnology | Series A | 700M |
7/2016 | Indigo | Series C | 100M |
8/2016 | Denali Therapeutics | Series B | 130M |
9/2018 | Indigo | Series E | 250M |
9/2017 | Indigo | Series D | 203M |
4/2022 | Tessera Therapeutics | Series C | 0 |
12/2021 | NorthLink Aviation | Venture Round | - |
11/2021 | Generate Biomedicines | Series B | 0 |
4/2021 | Repertoire Immune Medicines | Series B | 0 |
1/2021 | Tessera Therapeutics | Series B | 0 |
8/2020 | Indigo | Series F | 0 |
6/2020 | Sana Biotechnology | Series A | 0 |
9/2018 | Indigo | Series E | 0 |
11/2017 | Codiak Biosciences | Series C | 0 |
9/2017 | Indigo | Series D | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|